NASDAQ: AVBPArrivent Biopharma Inc Stock Ownership - Who owns Arrivent Biopharma?
Insider buying vs selling
Have Arrivent Biopharma Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Carl L. Gordon | Director | 2024-01-30 | 222,222 | $18.00 | $4.00MBuy |
| Carl L. Gordon | Director | 2024-01-30 | 222,222 | $18.00 | $4.00MBuy |
| James Healy | Director | 2024-01-30 | 444,444 | $18.00 | $8.00MBuy |
| Hillhouse Investment Management Ltd | 10% Owner | 2024-01-30 | 555,555 | $18.00 | $10.00MBuy |
| Orbimed Advisors LLC | Director | 2024-01-30 | 222,222 | $18.00 | $4.00MBuy |
| Orbimed Advisors LLC | Director | 2024-01-30 | 222,222 | $18.00 | $4.00MBuy |
AVBP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when AVBP insiders and whales buy or sell their stock.
AVBP Shareholders
What type of owners hold Arrivent Biopharma Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Hillhouse Investment Management Ltd | 14.67% | 4,484,672 | $69.69M | Insider |
| James Healy | 5.55% | 1,696,752 | $26.37M | Insider |
| Orbimed Advisors LLC | 4.95% | 1,513,664 | $23.52M | Insider |
| Carl L. Gordon | 4.95% | 1,513,664 | $23.52M | Insider |
| Zhengbin Yao | 2.01% | 613,138 | $9.53M | Insider |
| Robin Lachapelle | 1.61% | 491,494 | $7.64M | Insider |
| Stuart Lutzker | 0.48% | 147,744 | $2.30M | Insider |
| James Paul Kastenmayer | 0.02% | 7,386 | $114.78k | Insider |
AVBP vs Biotech Stocks
Arrivent Biopharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.